Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA
(RTTNews) - Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to developing innovative treatments for rare diseases.
Glassia is a liquid medicine for infusion containing human Alpha 1-Proteinase Inhibitor (A1-PI) also known as alpha-1 antitrypsin (A1AT), which is purified from human blood.
baca selengkapnya
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis
Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews
|
956 hari yang lalu
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia
Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.
RTTNews
|
1096 hari yang lalu
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease
Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews
|
1108 hari yang lalu
Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis
Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.
RTTNews
|
1110 hari yang lalu
Swiss Market Ends Modestly Higher
The Switzerland market ended modestly higher on Friday, after moving in a narrow range in positive territory right through the session. Lower oil prices and bond yields amid hopes about potential opening of the Strait of Hormuz in seven days lifted investor sentiment.
RTTNews
|
1 jam 10 menit yang lalu
European Stocks Rise On Oil Decline, Middle East Peace Hopes
European stocks rose Friday following a more than 2% decline in Brent crude futures and falling bond yields, supported by reports that Iran has submitted a proposal to end Middle East hostilities. Major indices including the DAX and FTSE 100 posted modest gains.
RTTNews
|
1 jam 38 menit yang lalu
U.S. Consumer Sentiment Drops Less Than Previously Estimated In September
Revised data released by the University of Michigan on Friday showed consumer sentiment in the U.S. deteriorated by less than previously estimated in the month of September. The University of Michigan said its consumer sentiment index for September was upwardly revised to 48.1 from a preliminary reading of 47.8.
RTTNews
|
5 jam 43 menit yang lalu
Bay Street Poised For Positive Open On Metal Gains
Higher gold and silver futures support Canadian stock sentiment Friday morning. Iranian officials have submitted peace proposals to U.S. mediators this week. BlackBerry's adjusted net income rose 79% to $43.2 mln in the second quarter.
RTTNews
|
7 jam 22 menit yang lalu
